hypersensitivity reactions, as well as the lack of a detailed understanding of their mechanism and of what triggers these reactions, any additional data in this field are valuable.
Finally, in 2008, Crichton et al. [13] speculated that Dextran 1 (not Isomaltoside 1000) interacts with anti-dextran antibodies when bound to a polynuclear iron core. Our data demonstrate that this is the case for Isomaltoside 1000. Notably, the rationale for the design of Iron isomaltoside 1000 was based on the "theoretically reduced anaphylactogenic potential" of the ligand [14, 15] . Thus, the conclusion that a non-immunogenic carbohydrate bound to a polynuclear iron core may form multivalent immune complexes and react with antibodies is important and may be valuable for the design of new intravenous iron preparations.
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